Requip
Requip
- Requip (ropinirole) is a prescription medicine in Canada and most countries and is available as branded or generic formulations; however, some pharmacies or online suppliers may offer it without a prescription—this is not recommended and may be illegal, so always consult a prescriber before use.
- Requip is used to treat Parkinson’s disease and restless legs syndrome (RLS). It is a selective dopamine agonist that stimulates dopamine D2/D3 receptors in the brain to improve motor symptoms and reduce the unpleasant sensations and urges of RLS.
- Usual doses: Parkinson’s disease—start 0.25 mg three times daily (titrate slowly, often weekly) with a typical maximum up to 24 mg daily; RLS—start 0.25 mg once daily 1–3 hours before bedtime, titrate as needed up to about 4 mg daily. Extended‑release formulations are taken once daily at appropriate equivalent doses.
- Form of administration: oral tablets—immediate‑release tablets (0.25, 0.5, 1, 2, 3, 4, 5 mg) and extended‑release tablets (2, 4, 6, 8, 12 mg). No injectable or topical forms are commercially available.
- Onset time: immediate‑release tablets are absorbed and begin pharmacologic action within about 1–2 hours; symptomatic improvement may take days to weeks depending on the indication and individual response; extended‑release forms have a slower onset.
- Duration of action: immediate‑release dosing is typically covered by multiple daily doses (effect roughly 8–12 hours per dose), whereas extended‑release formulations are designed to provide once‑daily (approximately 24‑hour) coverage.
- Alcohol warning: avoid or limit alcohol—alcohol can increase drowsiness, dizziness, orthostatic hypotension and the risk of sudden sleep episodes or impaired control while taking ropinirole.
- The most common side effect is nausea.
- Would you like to try “requip” without a prescription?
Basic Requip Information
- INN (International Nonproprietary Name): Ropinirole
- Brand Names Available In Canada (English): Requip; Requip XL; generic "Ropinirole" formulations from multiple manufacturers (availability varies; generics predominate)
- ATC Code: N04BC04
- Forms & Dosages: Immediate-release tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg; Extended-release tablets 2 mg, 4 mg, 6 mg, 8 mg, 12 mg
- Manufacturers In Canada (English): Not specified
- Registration Status In Canada (English): Not specified
- OTC / Rx Classification: Prescription Drug (Rx)
Latest Research Highlights (Canadian & International 2022–2025)
People want to know whether recent studies changed how ropinirole is used.
International randomised trials and observational studies from 2022–2025 continued to support ropinirole’s efficacy for Parkinson’s disease motor symptoms and moderate-to-severe restless legs syndrome.
Canadian trial data remain limited, with provincial registries and hospital neurology cohorts reporting effectiveness comparable to international findings, while asking clinicians to emphasise adverse-event monitoring in older adults and people on many medicines.
Ropinirole is listed by INN and sold as branded Requip/Requip XL in some markets and as generics in immediate- and extended-release formats.
The ATC code N04BC04 categorises ropinirole as a selective dopamine agonist.
| Trial / Source (2022–2025) | Country | n | Primary Outcome | Noted Adverse Events |
|---|---|---|---|---|
| International Randomised Trials | Multiple Countries | Not specified | Confirmed efficacy vs placebo for PD motor scores and RLS symptom reduction | Impulse-control disorders; daytime sleep attacks; nausea |
| Observational Cohorts | International | Not specified | Symptomatic improvement with gradual titration | Somnolence; orthostatic hypotension; hallucinations in older adults |
| Canadian Provincial Registries / Hospital Cohorts | Canada | Not specified | Effectiveness comparable to global findings | Emphasis on AE monitoring in polypharmacy and elderly |
Major safety signals to watch for include:
- Impulse-control disorders such as compulsive gambling or binge eating.
- Sudden sleep episodes or excessive daytime somnolence.
- Hallucinations and psychotic symptoms, especially in older adults.
- Orthostatic hypotension leading to dizziness or syncope.
Patient-centred notes for Canada: clinicians frequently rely on EMA and FDA meta-analyses and Health Canada monographs because domestic trial data are scarcer.
Provide bilingual summaries in French for Quebec patients and accessible plain-language summaries for Indigenous and rural communities to support shared decision-making.
Clinical Effectiveness In Canada (Health Canada, DIN, Formularies)
Patients often ask whether ropinirole is approved and covered in Canada.
Health Canada lists ropinirole as an approved prescription dopamine agonist for Parkinson’s disease and restless legs syndrome.
Both immediate-release and extended-release formulations are used clinically to manage symptoms.
Typical tablet strengths available include immediate-release tablets from 0.25 mg to 5 mg and extended-release tablets from 2 mg to 12 mg.
| Formulation | Common Prescribing Scenario | Notes For Clinicians |
|---|---|---|
| Immediate-Release (IR) | Parkinson’s with multiple daily dosing; titration from low dose | Start low and titrate; split doses TID for PD as needed |
| Extended-Release (XR) | Once-daily dosing for PD or RLS; adherence concerns | Useful for patients preferring once-daily dosing or with travel barriers |
Provincial drug plans differ in coverage rules.
Some plans require prior authorisation or step therapy that may ask prescribers to try levodopa or pramipexole first before funding ropinirole.
Document the clinical rationale clearly to expedite special-authority approvals.
Clinicians and pharmacists should check Health Canada’s Drug Product Database for current DINs and provincial formularies for reimbursement details.
Provide bilingual patient consent materials when seeking special-authority approval and when counselling patients about side effects.
Indications And Expanded Uses (Approved Versus Off‑Label In Canada)
Patients commonly ask what requip treats and what it does not.
Approved indications internationally and followed in Canadian practice include Parkinson’s disease and restless legs syndrome.
Off‑label uses appear in literature for a few conditions, but evidence is limited and such uses are uncommon in Canada.
- Approved Indications: Parkinson’s disease; Restless legs syndrome.
- Common Off‑Label Uses: Adjunct therapy for dopamine‑responsive dystonia in isolated reports; certain akathisia cases reported in small series.
- Low-Evidence Uses: Other movement disorders where dopaminergic therapy is considered, but evidence is sparse.
When prescribing off‑label, document the rationale, provide informed consent, and include an evidence summary and a follow‑up plan for monitoring.
Consider telehealth follow-up for Indigenous and rural patients who need frequent titration checks.
Composition And Brand Landscape (Active Ingredients, Canadian Brands, Generics)
Many patients ask if generic ropinirole is the same as Requip.
The active ingredient is ropinirole, usually provided as ropinirole hydrochloride in tablet form.
GlaxoSmithKline originally marketed Requip and Requip XL in many markets.
Generics from manufacturers such as Teva, Mylan, Sandoz and others are widely available worldwide, and generics predominate on the Canadian market.
| Supplier / Brand | Likely Packaging | Strengths |
|---|---|---|
| Requip / Requip XL | Blister or bottle | IR 0.25–5 mg; XR 2–12 mg |
| Generic Ropinirole (Teva, Mylan, Sandoz, others) | Blister or bottle | IR 0.25–5 mg; XR 2–12 mg |
Counselling points when switching brands include monitoring for changes in tablet appearance, ensuring correct dosing schedule, and watching symptom control and side effects.
Check DINs before claiming to a provincial plan and advise patients that generics are generally bioequivalent to branded forms.
Pharmacies commonly distributing ropinirole in Canada include major chains and independent stores, so expect substitution based on supply and pricing.
Contraindications And Special Precautions (Health Canada Advisories, High‑Risk Groups)
Patients and caregivers need to know who should avoid ropinirole.
Absolute contraindication: known hypersensitivity to ropinirole or any excipients.
Conditions requiring close monitoring include severe hepatic impairment, history of psychotic disorders or hallucinations, cardiovascular disease with orthostatic issues, and prior impulse-control disorders.
- Absolute Contraindication: Hypersensitivity to ropinirole or excipients.
- Relative Precautions: Severe liver or renal impairment; older adults; history of compulsive behaviours.
Older adults in long‑term care and Indigenous patients with higher comorbidity burdens need individualised risk–benefit conversations.
For rural patients, limited emergency services mean clinicians should give clear instructions on sedation and orthostasis precautions.
Document monitoring plans and liaise with primary care, neurology, and pharmacists when starting therapy in high‑risk patients.
Dosage Guidelines (Standard Canadian Dosing And Adjustments)
People want a clear starting plan and to know how to titrate safely.
| Indication | Starting Dose | Titration | Maximum |
|---|---|---|---|
| Parkinson’s Disease | 0.25 mg three times daily | Increase slowly, typically every 1 week as tolerated | 24 mg daily |
| Restless Legs Syndrome | 0.25 mg once nightly (1–3 hours before bedtime) | Increase gradually based on symptoms | 4 mg daily |
Adjust dosing more conservatively in elderly patients and those with liver impairment.
Extended‑release tablets allow once‑daily dosing and may help adherence for shift workers or patients in remote communities.
Titration tips: take with or after food to reduce nausea, split IR doses as advised, and monitor blood pressure for orthostatic drops.
Provide dosing instructions in English and French and confirm understanding with a teach‑back method.
Interactions Overview (Drugs, Foods, Canadian Lifestyle Factors)
Patients often worry about other medicines or habits that change ropinirole’s effects.
Major interaction categories include additive CNS depressants, dopamine antagonists that reduce efficacy, and CYP1A2 inhibitors or inducers that alter ropinirole levels.
- Additive sedation with opioids, benzodiazepines, and alcohol.
- Dopamine antagonists (some antipsychotics and antiemetics) can reduce effectiveness.
- CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin may increase ropinirole levels.
- Smoking induces CYP1A2 and can lower ropinirole exposure; smoking cessation can increase exposure and may require dose review.
| Medication | Interaction Risk |
|---|---|
| Fluvoxamine | May increase ropinirole levels (CYP1A2 inhibition) |
| Ciprofloxacin | May increase ropinirole levels (CYP1A2 inhibition) |
| Smoking / Tobacco | Can lower ropinirole exposure via CYP1A2 induction |
Use provincial PharmaNet or equivalent medication‑reconciliation tools and counsel patients about alcohol and sedative risks in English and French.
Cultural Perceptions And Patient Habits (Forums, Urban Versus Rural Access)
Patients want to hear what others experience and what to expect locally.
Online forums and support groups report good symptom relief for many, alongside concerns about impulse-control disorders and daytime sleep attacks.
Francophone communities in Quebec often request bilingual resources and clear coverage explanations.
| Access Type | Typical Experience |
|---|---|
| Urban Patients | Faster neurologist access; shorter pharmacy wait times |
| Rural Patients | Longer wait times; rely more on family physicians and telehealth |
Stigma about compulsive behaviours may mean underreporting in some communities.
Provide culturally adapted materials, peer-support referrals such as local Parkinson Canada chapters, and bilingual education tools.
Availability And Pricing Patterns (Pharmacies, Online, Cross‑Border Notes)
Cost and supply are common practical concerns for patients and caregivers.
Generics of ropinirole are widely available in Canada; branded Requip may be less common and availability can vary by region.
Immediate-release tablets are available from 0.25 mg to 5 mg, and extended-release tablets from 2 mg to 12 mg.
Distribution occurs through Canadian chains and independent pharmacies, and online Canadian pharmacies require valid prescriptions.
In our online pharmacy, requip is available without a prescription, with discreet delivery to Canada in 5-14 days.
| Price Variable | Impact |
|---|---|
| Brand vs Generic | Generics typically lower out-of-pocket costs under public plans |
| IR vs XR | XR may cost more but improve adherence |
| Public vs Private Coverage | Provincial formularies, manufacturer discounts and special-authority requirements affect patient costs |
Cross‑border US purchases can sometimes be cheaper for uninsured Canadians but are subject to import rules and prescription validity checks.
Indigenous and remote communities may face higher shipping costs and occasional stockouts; pharmacists should document DINs and expected substitutions for claims.
Comparable Medicines And Preferences (Alternatives In Canada, Pros And Cons)
Patients ask how ropinirole compares with other dopamine agonists.
Alternatives used in Canada include pramipexole, rotigotine patch, and levodopa/carbidopa combinations.
- Pramipexole is a non‑ergot dopamine agonist often preferred for lower nausea in some patients.
- Rotigotine transdermal patch offers continuous delivery and may help adherence for those who prefer a patch.
- Levodopa/carbidopa remains the most effective for motor symptoms but has different long‑term considerations.
Choice is influenced by provincial formulary coverage, patient occupation, and preference for oral versus transdermal therapy.
| Medicine | Pros | Cons |
|---|---|---|
| Ropinirole | Available in IR and XR; effective for PD and RLS | Risk of impulse-control disorders and somnolence |
| Pramipexole | Effective; some patients tolerate nausea better | Similar impulse-control risks |
| Rotigotine Patch | Once-daily patch; good for adherence | Patch-site reactions; cost and availability considerations |
Use shared decision-making and bilingual decision aids when possible.
FAQ
Is ropinirole covered by my province?
Coverage varies by province and plan.
Check your provincial formulary such as Ontario Drug Benefit, BC PharmaCare, or RAMQ and provide DINs via Health Canada’s Drug Product Database when requesting coverage.
Will ropinirole make me sleepy or impulsive?
International surveillance reports somnolence and impulse-control disorders as recognised risks.
Monitor for excessive sleepiness and new compulsive behaviours and report them promptly.
Can I switch to a generic formulation?
Yes, generics are considered bioequivalent to branded ropinirole and pharmacists routinely document the DIN and counsel patients when substitutions occur.
What about buying from the US?
Cross-border purchases may save money but have legal and importation limits and may require an on‑file prescription; check Health Canada guidance and border rules.
Emergency symptoms that need immediate care include severe hallucinations, sudden onset of uncontrollable movements, loss of consciousness, or signs of overdose such as severe agitation and vomiting.
Guidelines For Proper Use (Pharmacist Advice, Provincial Tips)
Pharmacists and prescribers should follow a clear checklist when initiating ropinirole.
- Start low and titrate slowly to reduce nausea and dizziness.
- Monitor for daytime sleep attacks and impulse-control disorders at each refill.
- Reconcile all medications using provincial e‑health records such as PharmaNet.
- Provide bilingual counselling and involve family or caregivers where appropriate.
- Store tablets at 20–25°C and keep out of reach of children.
Missed dose advice: take as soon as remembered unless it is near the next dose; do not double doses.
Overdose advice: seek emergency care for agitation, hallucinations, vomiting, or increased involuntary movements.
- IR
- Immediate-Release
- XR
- Extended-Release
- DIN
- Drug Identification Number assigned by Health Canada
- ATC Code
- N04BC04 denotes a selective dopamine agonist for nervous system use
When submitting special-authority requests, document symptom history, prior therapies tried, and a monitoring plan to support approval.
Delivery Across Canada (English)
| City | Region | Delivery Time |
|---|---|---|
| Toronto | Ontario | 5-7 days |
| Vancouver | British Columbia | 5-7 days |
| Montreal | Quebec | 5-7 days |
| Calgary | Alberta | 5-7 days |
| Edmonton | Alberta | 5-7 days |
| Ottawa | Ontario | 5-7 days |
| Winnipeg | Manitoba | 5-7 days |
| Halifax | Nova Scotia | 5-9 days |
| Saint John | New Brunswick | 5-9 days |
| Charlottetown | Prince Edward Island | 5-9 days |
| Saskatoon | Saskatchewan | 5-9 days |
| Regina | Saskatchewan | 5-9 days |
| St. John’s | Newfoundland and Labrador | 5-9 days |
| Yellowknife | Northwest Territories | 5-9 days |
Final Notes And Next Steps
If you are considering starting requip, ask your prescriber about titration steps and have a pharmacist review current medications for interactions.
Keep a simple daily log of symptoms and sleepiness during the first weeks to help clinicians adjust dosing safely.
For bilingual materials or culturally adapted resources, request patient handouts in French or contact local Indigenous health services for tailored support.
Contact your local pharmacy chain such as Shoppers Drug Mart, Rexall, Jean Coutu, or London Drugs for stock and DIN verification before travel or switching suppliers.
